The Motley Fool Australia
2h ago
CSL faces 18 August FY26 result as shares slide 52% across FY26
CSL will release an FY26 earnings update in August 2025 showing revenue of US$8.3 billion, down 4% year on year, and underlying NPATA of US$1.9 billion, down 7%. The stock is down 52% across FY26, making it one of the worst performers in the ASX 200. The company also announced large-scale job cuts, plans to demerge its influenza vaccine business, and expects about US$5 billion in noncash, pretax impairments across FY26–FY27. The developments have weighed on sentiment toward ASX 200 constituents and broader market mood.